Immunogenic cell death and DAMPs in cancer therapy
HGF/c-Met signaling is a well-established oncogenic pathway: c-Met is amplified or overexpressed in multiple cancers (gastric, lung, renal, hepatocellular) HGF/c-Met activation promotes tumor cell proliferation, survival, invasion, and metastasis c-Met inhibitors are FDA-approved cancer drugs (cabozantinib, crizotinib, capmatinib) A compound that potentiates HGF/c-Met signaling raises theoretical concerns about promoting tumor growth or transformation with chronic use
Subcutaneous Injections A less invasive option, with benefits typically noticeable within a day or two
Como qualquer substncia biologicamente ativa, eles podem provocar efeitos colaterais
Error probabilities (in Eng)
As a physician, my primary commitment is to your health and safety